|
مقاله
|
Abstract
|
|
|
Title:
|
Minimal Dose of Intravitreal Bevacizumab (0.25 mg/0.01 mL) in the Treatment of Retinopathy of Prematurity
|
Author(s):
|
Alireza khodabande
|
Presentation Type:
|
Oral
|
Subject:
|
Posterior Segment and Uveitis
|
Others:
|
|
Presenting Author:
|
|
Name:
|
Ali reza Khoda Bandeh
|
Affiliation :(optional)
|
Farabi eye hospital
|
E mail:
|
alireza_khodabande@yahoo.com
|
Phone:
|
|
Mobile:
|
09132137426
|
|
|
Purpose:
|
To determine whether a very low dose (0.25 mg/0.01 mL) of intravitreal bevacizumab is effective in the regression of type 1 retinopathy of prematurity (ROP).
|
Methods:
|
: This prospective, noncomparative, interventional case-series included all infants who consecutively received 0.25 mg/0.01 mL of intravitreal bevacizumab for type 1 ROP. Infants were followed up for ROP persistence/recurrence until 90 weeks’ postmenstrual age.
|
Results:
|
Forty-nine eyes of 25 consecutive infants [1-6] (24 bilateral and one unilateral) underwent an intravitreal injection of a reduced dose (0.25 mg/0.01 mL) of intravitreal bevacizumab. ROP regressed in all eyes. No plus disease/ neovascularization recurrence occurred until 90 weeks’ postmenstrual age.
|
Conclusion:
|
eyes with type 1 ROP did not have recurrent plus disease or neovascularization with 0.25mg/0.01mL intravitreal bevacizumab treatment. No safety issues were attributable to bevacizumab during the study period
|
Attachment:
|
|
|
|